Previous 10 | Next 10 |
Innovation Pharmaceuticals (OTCQB:IPIX) said it acquired a minority stake in Israeli medical device maker Squalus Medical. IPIX said Squalus is developing a novel laser-based thermal ablation technology called StingRay Laser System to treat previously inoperable cases of epilepsy an...
Innovation Pharmaceuticals acquires a minority ownership Squalus has invented and is developing a leading-edge image guided surgical laser platform for treating previously inoperable cases of epilepsy and for enabling new treatment options for cancer cases in multiple key specialties, ...
In other news, Scientific Advisor, William F. DeGrado, PhD, gives keynote lecture at 2021 Faraday Discussion and co-awarded John Scott Medal WAKEFIELD, MA / ACCESSWIRE / March 15, 2022 / Innovation Pharmaceutical s (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical ...
WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's Brilacidin Phase 2 COVID-19 study and compassionate use of Brilacidin in critically-ill ...
WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on the Company's go-forward strategy heading into 2022. The Company is pleased to report that as...
WAKEFIELD, MA / ACCESSWIRE / November 18, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on clinical development plans for Brilacidin, the Company's defensin-mimetic drug candidate being evaluated in clinic...
Additionally, new in vitro data also show Brilacidin targets both viral proteins and host factors, suggesting Brilacidin would be less prone to developing resistance compared to other antivirals WAKEFIELD, MA / ACCESSWIRE / November 12, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("t...
WAKEFIELD, MA / ACCESSWIRE / November 11, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported topline results from the Company's Phase 2 clinical trial of Brilacidin in hospitalized patients with moderate-to-severe COVID-...
WAKEFIELD, MA / ACCESSWIRE / November 3, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical-stage biopharmaceutical company, today announced that the Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brila...
WAKEFIELD, MA / ACCESSWIRE / October 25, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced the Company anticipates reporting topline results the week of November 8 th from its Phase 2 clinical trial of Brilacidin for ...
News, Short Squeeze, Breakout and More Instantly...
Innovation Pharmaceuticals Inc Company Name:
IPIX Stock Symbol:
OTCMKTS Market:
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to provide shareho...
WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States Patent and Trade Office (USPTO), on June 6, 2023, granted a patent, &...
WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to inform sh...